# Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma

> **NCT03349255** · PHASE1 · TERMINATED · sponsor: **Aeon Therapeutics (Shanghai) Co., Ltd.** · enrollment: 3 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Cancer
- Liver Neoplasms
- Metastatic Liver Cancer

## Interventions

- **BIOLOGICAL:** autologous ET1402L1-CART cells

## Key facts

- **NCT ID:** NCT03349255
- **Lead sponsor:** Aeon Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-06
- **Primary completion:** 2019-01-10
- **Final completion:** 2019-01-10
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Will study new T-cell construct for the same indication
- **Last updated:** 2019-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03349255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03349255, "Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03349255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*